From: BIRC5 expression by race, age and clinical factors in breast cancer patients
 | CBCS | CBCS | TCGA | |||
---|---|---|---|---|---|---|
RFD (95% CI)a | RFD (95% CI)b | OR (95% CI)a | OR (95% CI)b | OR (95% CI)a | OR (95% CI)b | |
Age | ||||||
 ≥ 50 years | Ref | Ref | Ref | Ref | Ref | Ref |
 < 50 years | 12.1 (8.5—15.6) | 6.8 (3.6—7.9) | 2.0 (1.7—2.5) | 2.0 (1.6—2.4) | 1.5 (1.1—2.0) | 1.5 (1.0—2.1) |
Race | ||||||
 Non-Black | Ref | Ref | Ref | Ref | Ref | Ref |
 Black | 11.7 (8.2—15.1) | 4.2 (1.0—7.6) | 1.9 (1.6—2.4) | 1.4 (1.1—1.7) | 3.2 (2.3—4.5) | 2.8 (1.9—4.1) |
ER status | ||||||
 ER-Positive | Ref | Ref | Ref | Ref | Ref | Ref |
 ER-Negative | 27.3 (23.1—31.4) | 26.6 (22.4—30.8) | 4.3 (3.5—5.3) | 4.2 (3.4—5.2) | 6.5 (4.7—9.2) | 6.3 (4.4—8.9) |
PR status | ||||||
 ER-positive | Ref | Ref | Ref | Ref | Ref | Ref |
 ER-negative | 21.1 (17.4—24.9) | 6.8 (2.3—11.7) | 3.5 (2.8—4.4) | 1.7 (1.3—2.3) | 6 (4.3—8.3) | 3 (1.9—4.6) |
Her2 status | Â | Â | Â | Â | Â | Â |
 Her2-Negative | Ref | Ref | Ref | Ref | Ref | Ref |
 Her2-Positive | 0.71 (-3.75—5.54) | DNC | 1.0 (0.7—1.3) | 0.9 (0.7—1.2) | 1 (0.6—1.5) | 0.8 (0.5—1.3) |
PAM50 subtype | ||||||
 LumA | Ref | Ref | Ref | Ref | Ref | Ref |
 LumB | 33.0 (27.6—38.5) | DNC | 16.7 (11.1—25.7) | 16.7 (11.1—25.7) | 13.9 (8.3—23.9) | 13.5 (8.1—23.2) |
 HER2-enriched | 28.4 (21.9—35.3) | DNC | 13.1 (8.3—21.2) | 11.5 (7.0—19.2) | 10.6 (5.5—20.6) | 9.7 (4.9—19.0) |
 Basal | 49.8 (45.4—54.2) | DNC | 31.9 (21.8—48.2) | 26 (16.3—42.5) | 53 (31.4—93.2) | 51.7 (30.3—91.7) |
Tumor stage | ||||||
 Stage I | Ref | Ref | Ref | Ref | Ref | Ref |
 Stage II | 9.5 (5.8—13.2) | 6.2 (2.8—9.7) | 1.8 (1.4—2.4) | 1.7 (1.3—2.1) | 2.1 (1.4—3.4) | 2.1 (1.3—3.5) |
 Stage III/IV | 7.3 (2.3—12.7) | 4.8 (0.2—9.8) | 1.6 (1.2—2.2) | 1.4 (1.0—2.0) | 1.7 (1.0—2.8) | 1.8 (1.0—3.2) |
Tumor size | ||||||
 ≤ 2 cm | Ref | Ref | Ref | Ref | NA | NA |
 > 2–5 cm | 12.7 (9.0—16.4) | 9.1 (5.7—12.7) | 2.2 (1.7—2.7) | 2 (1.6—2.5) | NA | NA |
 > 5 cm | 14.7 (8.5—21.3) | 9.9 (4.0—16.2) | 2.4 (1.7—3.3) | 2 (1.4—2.8) | NA | NA |